Intercept Pharmaceuticals Inc. (ICPT)’s Positive Liver Cure Overshadows Dismal Second Quarter Results

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) continues to soar in the market after the release of positive clinical data, which showed its drug for a lesser known liver disease is effective; increasing prospects of the same being approved by the FDA. The drug released is called OCA and was found to reverse liver damage by essentially reversing liver scarring or fibrosis, which is most of the time known to cause organ failure or cancer.

Intercept Pharmaceuticals Inc (NASDAQ:ICPT)

“[…] the results are very good, better than we thought. This stock has been up a lot and what happens is I think people like exact sciences. They recognize, you know, what it is a lottery, you have a bunch of this stocks, and one of them is going to pay off, and that’s why the stock market is vibrant because when you have a great orphan drug that does do something special you can have this kind of move,” said CNBC’s Jim Cramer.

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) has already outlined plans to release  full trial results on November 10, 2014 at the American Association study of the Liver Diseases conference in Boston. The pharmaceutical company has also outlined plans to target the drug first on Primary Biliary Cirrhosis, a rare form disease known to cause inflammation that destroys the bile ducts in the liver ultimately leading to scarring.

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT)’s stock is already at a high of $295.42 having surged by 24.56% on the release of the positive news awaiting to see the final trading share price as of the close of business. Genfit another French pharmaceutical company has stated that it is developing its own experimental drug, GFT505, which treats NASH.

Genfit and Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) have also stated that plans are underway, to explore partnerships with other drug makers with a view of bringing similar treatment to the market. The release of the positive OCA drug news, looks to have overshadowed dismal quarterly results that the company posted yesterday; having posted an adjusted net loss of $1 a share compared to a net loss of $0.79 reported a year ago.

Disclosure: none

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Largest Pharmaceutical Companies In the World

The 10 Most Expensive Android Apps

The 9 Most Expensive Designer Bags in the World

The 7 Most Expensive Real Estate in the World

The 10 Most Expensive eBay Items Ever Sold

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!